Ascendis Pharma A/S (ASND) Q1 2018 Earnings Results

Ascendis Pharma Misses on EPS, Stock Down 0.92%

Ascendis Pharma reported a loss of $1.07 per share, but there was no revenue data available for comparison. The stock reacted negatively, declining by 0.92%. The lack of guidance and key commentary from management may leave investors uncertain about the company's future direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.07	N/A	—
Revenue	N/A	N/A	—

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Ascendis Pharma Misses on EPS, Stock Down 0.92%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma Misses on EPS, Stock Down 0.92%

Key numbers

Management commentary